Quantum Computing Needs To Be Economical, Diraq Argues.

Millions of candidate molecules are sifted through by classical computers before pharmaceutical researchers even begin lab synthesis, a process that emphasises the substantial computational power already applied to early drug discovery. Diraq contends quantum computers must be both economical and deployable to achieve true utility, as the pharmaceutical pipeline progresses from a “target-to-hit” stage to a “hit-to-lead” stage where most candidates are quickly discarded. The potential value, the company suggests, lies in making better decisions earlier in the process.

Quantum Chemistry Limits Impact Drug Discovery Economics

Early assessments of quantum computing’s potential in drug discovery, dating back to 2010, already highlighted the need for practical value alongside theoretical capability. Diraq’s calculations indicate that even a utility-scale quantum computer might struggle to serve more than a handful of drug programs simultaneously, meaning the technology must deliver value early in the process to affect overall costs, the company says. A slightly more accurate prediction in molecular modeling, while not on its own, can significantly reduce the risk of pursuing unsuccessful candidates through expensive later stages.